Over the forecast period, the high cost of drug development is anticipated to drive market expansion for computational biology. For instance, a March 2020 review in JAMA found that between 2009 and 2018, U.S. biopharmaceutical companies spent over US$ 1 billion to bring each of their new medications to market.
Additionally, a number of advantages of computational biology are anticipated to support market expansion. Computational biology's predictive modelling tools can offer priceless insight into how to more effectively streamline the drug development process. Clinical trials can be completed faster and with fewer patients overall thanks to predictive modelling.
The market for Computational Biology was valued at US$ 3,453.2 Mn in 2019 and is anticipated to grow at a CAGR of 17.6% from 2020 to 2027 to reach US$ 12,601.1 Mn.
Prominent Players in the Computational Biology Industry:
1. Accelrys: An organisation that offers digital programmes and business consulting services to help its clients' businesses adapt more quickly. Through the use of cutting-edge digital tactics, the company's services assist CEOs who are in charge of teams who sell high-end B2B goods and services by assisting clients in accelerating growth, innovation, and business transformation. Established in 2008.
2. Certara, L.P: By transforming conventional drug discovery and development with biosimulation software and technology, Certara Inc. expedites the delivery of medications to patients. In order to shorten clinical trials, speed up regulatory approval, and improve patient access to medicines, it offers clients modelling and simulation, regulatory science, and evaluation tools and services. United States headquarters. The acquisition of Pinnacle 21, a top supplier of SaaS solutions for clinical data fitness, regulatory compliance, and submission preparedness, has now been completed, according to Certara, Inc. (Nasdaq: CERT), a world leader in biosimulation.
3. Chemical Computing Group Inc.: The creator of molecular modelling software aimed to find, use, and validate the novel methodological approach. Created in 1994. Head office in Canada. A firm that creates cutting-edge IT solutions for life sciences research, Discngine SAS ("Discngine"), was purchased by Chemical Computing Group ULC ("CCG"), according to a press release today. The headquarters of Discngine are in Paris, France.
4. Compugen, Ltd.: In order to create medicines for the field of cancer immunotherapy, Compugen Ltd., a clinical-stage therapeutic discovery and development business, uses its broadly applicable predictive computational discovery capabilities to uncover novel drug targets and new biological pathways. Established in 1993. Head office in Israel. Following the administration of the first patient with TIGIT Bispecific derived from COM902 in 2021, Compugen will announce a milestone payment from AstraZeneca.
5. Entelos, Inc. (Rosa & Co. LLC): Creator of predictive biosimulation technology designed to improve the identification, creation, and application of therapeutics. Established in 1996. Admin centre in the U.S.
6. Genedata AG: The creator of a platform for end-to-end data management that integrates data collection, processing, and reporting throughout the whole biopharmaceutical research and development process. Built in 1997. Base of operations in Basel, Switzerland.
7. Insilico Biotechnology AG: Enterprise software solutions provider for predictive biomanufacturing using a virtual representation of a real-world living or non-living thing. Established in 2001. German headquarters are in Stuttgart. Insilico Biotechnology, a creator of cutting-edge digital twin technology for bioprocesses, is acquired by Yokogawa.
Definition: A field of science that uses computers, databases, math, and statistics to collect, store, organize, and analyze large amounts of biological, medical, and health information.
